<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222843</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-III-ITP</org_study_id>
    <nct_id>NCT03222843</nct_id>
  </id_info>
  <brief_title>Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient</brief_title>
  <official_title>A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with
      chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain
      platelet counts 50~250×109/L
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with a platelet count ≥50×109/L after Day 57.</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral hetrombopag at an initial dose of 2.5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral hetrombopag at an initial dose of 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo at an initial dose of 2.5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo at an initial dose of 5 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <description>once daily</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of ITP ≥6 months;Platelets &lt;30×109/L.

          2. No evidence of other causes of thrombocytopenia.

          3. Subjects who are refractory or have relapsed after at least one prior ITP therapy.

          4. Previous therapy for ITP including rescue must have been completed at least 2 weeks
             prior to randomization.

          5. Subjects treated with maintenance immunosuppressive therapy must be receiving a dose
             that has been stable for at least 1 month.

          6. PT result no exceed normal by more than ±3s,APTT result no exceed normal by more than
             ±10s.

          7. Signed informed consent.

        Exclusion Criteria:

          1. Patients with any prior history of arterial or venous thrombosis，or diagnosis as
             Thrombophilia.

          2. Subjects diagnosed with tumor.

          3. Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to
             increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a
             Corrected QT interval (QTc) &gt;450msec or QTc &gt;480 for patients with a Bundle Branch
             Block.

          4. Female subjects who are nursing or pregnant at screening or pre-dose on baseline.

          5. Subjects who have previously received eltrombopag or any other thrombopoietin receptor
             agonist within 30 days .

          6. Subject has consumed aspirin, aspirin-containing compounds, salicylates,
             anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for &gt;3
             consecutive days within 2 weeks of the study start and until the end of the study.

          7. Any laboratory or clinical evidence for HIV infection.Any clinical history for
             hepatitis C infection; chronic hepatitis B infection; or any evidence for active
             hepatitis at the time of subject screening.

          8. ALT&gt; 1.5 x upper limit of normal (ULN), AST&gt; 3 x upper limit of normal (ULN)) DBLI&gt;
             1.2 x upper limit of normal (ULN),Scr&gt; 1.2 x upper limit of normal (ULN)

          9. The subject has participated in other clinical trial within the 3 months prior to
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Hu, Ph.D</last_name>
      <email>dr_huyu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Heng Mei, Ph.D</last_name>
      <email>mayheng@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ting Niu, MD</last_name>
      <email>tingniu@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renchi Yang, MD</last_name>
      <email>rcyang65@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

